18F-FDG PET/CT显像在肉瘤样肝细胞癌中的应用
本文报告一例53岁男性肝IV/VIII段肿瘤患者,肿瘤标志物均在参考范围内,18F-FDG PET/CT显示肿瘤强烈摄取,免疫组化证实为肉瘤样肝细胞癌;经6个周期PD-1治疗后,随访CT超过2年未见复发或转移。
要点
- 肉瘤样肝细胞癌是肝细胞癌的罕见亚型,肿瘤标志物可均在参考范围内。
- 18F-FDG PET/CT显示肿瘤强烈摄取,免疫组化可确诊肉瘤样肝细胞癌。
- 本例经6个周期PD-1治疗后,随访CT超过2年未见复发或转移。
核心结论
- 报告一例肉瘤样肝细胞癌经PD-1治疗达到完全缓解的病例,为肉瘤样肝细胞癌的诊断和治疗提供一定帮助。
研究设计与样本
- 个案报告:53岁男性,肝IV/VIII段肿瘤,肿瘤标志物均在参考范围内,经免疫组化确诊为肉瘤样肝细胞癌。
主要发现
- 18F-FDG PET/CT显示肿瘤强烈摄取。
- 免疫组化证实为肉瘤样肝细胞癌。
- 经6个周期PD-1治疗后,随访CT超过2年未见复发或转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sarcomatoid hepatocellular carcinoma is a rare subtype of hepatocellular carcinoma. We present a 53-year-old man with a hepatic IV/VIII segment neoplasm whose tumor markers were all in the reference range. The neoplasm presented intense uptake of 18F-FDG and was confirmed as sarcomatoid hepatocellular carcinoma by immunohistochemistry. After 6 cycles of PD-1 treatment, no recurrence or metastasis was found by follow-up CT over 2 years. Thus, we reported a case of sarcomatoid hepatocellular carcinoma with complete remission to PD-1 treatment and provided some help for the diagnosis and treatment of sarcomatoid hepatocellular carcinoma.
引用
- Yang T, Zou MH, Zou Q, et al. 18F-FDG PET/CT Imaging in Sarcomatoid Hepatocellular Carcinoma. Clin Nucl Med. 2022. PMID: 35293354. doi:10.1097/RLU.0000000000004121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。